BR112016029848A2 - proteínas de fusão mic-1 e utilizações das mesmas - Google Patents

proteínas de fusão mic-1 e utilizações das mesmas

Info

Publication number
BR112016029848A2
BR112016029848A2 BR112016029848A BR112016029848A BR112016029848A2 BR 112016029848 A2 BR112016029848 A2 BR 112016029848A2 BR 112016029848 A BR112016029848 A BR 112016029848A BR 112016029848 A BR112016029848 A BR 112016029848A BR 112016029848 A2 BR112016029848 A2 BR 112016029848A2
Authority
BR
Brazil
Prior art keywords
mic
compounds
fusion proteins
relates
fusion
Prior art date
Application number
BR112016029848A
Other languages
English (en)
Inventor
Christian Shaw Allan
HELGSTRAND Charlotte
Thøgersen Henning
Vilbour Andersen Kim
Sass-Ørum Kristian
Paolo Bastner SANDRINI Michael
Beck Jørgensen Sebastian
Hastrup Sven
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112016029848A2 publication Critical patent/BR112016029848A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se a, proteínas de fusão mic-1. mais especificamente, refere-se a compostos que compreendem proteínas de fusão compreendendo uma proteína mic-1 ou um análogo desta, no térmico c da proteína de fusão e uma variante funcional de soro albumina humana no término n da proteína de fusão ligada via um ligante peptídico. os compostos da invenção apresentam atividade de mic-1. a invenção também se refere às composições farmacêuticas que compreendem tais compostos e excipientes farmaceuticamente aceitáveis, bem como, o uso medicinal dos compostos.
BR112016029848A 2014-06-24 2015-06-17 proteínas de fusão mic-1 e utilizações das mesmas BR112016029848A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173664 2014-06-24
PCT/EP2015/063596 WO2015197446A1 (en) 2014-06-24 2015-06-17 Mic-1 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
BR112016029848A2 true BR112016029848A2 (pt) 2017-10-24

Family

ID=51032955

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029848A BR112016029848A2 (pt) 2014-06-24 2015-06-17 proteínas de fusão mic-1 e utilizações das mesmas

Country Status (15)

Country Link
US (2) US9272019B2 (pt)
EP (1) EP3160496B1 (pt)
JP (1) JP6696915B2 (pt)
KR (1) KR20170020383A (pt)
CN (1) CN106459222A (pt)
AR (1) AR100945A1 (pt)
AU (1) AU2015279525A1 (pt)
BR (1) BR112016029848A2 (pt)
CA (1) CA2952293A1 (pt)
IL (1) IL249327A0 (pt)
MX (1) MX2016016063A (pt)
RU (1) RU2017101436A (pt)
TW (1) TW201613958A (pt)
WO (1) WO2015197446A1 (pt)
ZA (1) ZA201608214B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
EP3027642B1 (en) 2013-07-31 2020-08-19 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MX2018014023A (es) * 2016-05-24 2019-04-04 Novo Nordisk As Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos.
GB201615844D0 (en) * 2016-09-16 2016-11-02 Genagon Therapeutics Ab Agents for use in therapy
EP3551214B1 (en) * 2016-12-06 2024-03-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
GB201700553D0 (en) * 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
CN110770251A (zh) * 2017-04-20 2020-02-07 诺和诺德股份有限公司 纯化白蛋白融合蛋白的方法
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
US11260108B2 (en) 2017-09-10 2022-03-01 Novo Nordisk A/S MIC-1 and GLP-1 for use in the treatment of obesity
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
AU2019253462A1 (en) 2018-04-09 2020-11-26 Amgen Inc. Growth differentiation factor 15 fusion proteins
JP2021533743A (ja) 2018-08-10 2021-12-09 ノバルティス アーゲー Ｇｆｒａｌ細胞外ドメイン及び使用方法
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CA3161266A1 (en) * 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
EP4085077A4 (en) * 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
KR102195740B1 (ko) * 2020-03-25 2020-12-28 서울대학교산학협력단 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
WO2021194257A1 (ko) * 2020-03-25 2021-09-30 (주) 업테라 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
WO2022089435A1 (en) * 2020-10-27 2022-05-05 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof
CN112694520B (zh) * 2020-12-02 2023-01-17 图凌(杭州)生物医药有限公司 一种人工多肽hm、其抗体及在病理检测中的应用
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
TW202342014A (zh) 2022-02-10 2023-11-01 瑞士商諾華公司 １，３－苯并二氧戊環衍生物
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1276756A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
EP2774620A1 (en) 2004-04-13 2014-09-10 St Vincent's Hospital Sydney Limited Method for modulating weight loss
PT1751184E (pt) * 2004-05-13 2009-11-10 Lilly Co Eli Proteínas de fusão de fgf-21
KR100891509B1 (ko) * 2004-07-26 2009-04-06 아스테리온 리미티드 연결체들
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
BR112014018575A2 (pt) * 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
WO2013148117A1 (en) * 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
BR112015018104A2 (pt) 2013-01-30 2017-11-21 Ngm Biopharmaceuticals Inc polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
EP3027642B1 (en) 2013-07-31 2020-08-19 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs

Also Published As

Publication number Publication date
AR100945A1 (es) 2016-11-09
US20160129083A1 (en) 2016-05-12
TW201613958A (en) 2016-04-16
ZA201608214B (en) 2018-11-28
JP6696915B2 (ja) 2020-05-20
EP3160496A1 (en) 2017-05-03
RU2017101436A3 (pt) 2019-02-13
CN106459222A (zh) 2017-02-22
RU2017101436A (ru) 2018-07-24
AU2015279525A1 (en) 2016-12-15
EP3160496B1 (en) 2021-03-03
MX2016016063A (es) 2017-03-10
CA2952293A1 (en) 2015-12-30
US20160015784A1 (en) 2016-01-21
JP2017528419A (ja) 2017-09-28
US9272019B2 (en) 2016-03-01
US9956264B2 (en) 2018-05-01
IL249327A0 (en) 2017-02-28
WO2015197446A1 (en) 2015-12-30
KR20170020383A (ko) 2017-02-22

Similar Documents

Publication Publication Date Title
BR112016029848A2 (pt) proteínas de fusão mic-1 e utilizações das mesmas
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112017011552A2 (pt) derivados de fgf21 e seu uso
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
MX2020011333A (es) Uso terapeutico de proteinas morfogeneticas oseas.
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
MD3359146T2 (ro) Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
DK3604304T3 (da) Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
BR112015018264A2 (pt) Composições nutricionais contendo um componente peptídico e usos das mesmas
BR112017008734A2 (pt) acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau
BR112016016356A2 (pt) Imunoterapia baseada em lipossomas
BR112015013223A2 (pt) composição farmacêutica
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
TN2015000129A1 (en) POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
CL2014003048A1 (es) Compuestos derivados de n-[(3-cloro-6,7,10,11-tetrahidro-9-metil-7,11-metanocicloocta[b]quinolin-12-il)amino]-9,10-dihidro-4,5-dihidroxi-9,10-dioxoantraceno-2-carboxamida; procedimiento para prepararlos; composicion farmaceutica; compuestos intermediarios; y uso para la prevencion y/o tratamiento de la enfermedad de alzheimer.
EP3603659A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY RESPIRATORY DISEASE, BASED ON CELL PERMEABLE PEPTIDE FUSION PROTEIN AND CTCTLA4 PEPTIDE, CONTAINED AS ACTIVE INGREDIENT IN THIS COMPOSITION
BR112017002193A2 (pt) peptídeo derivado de urlc10 e vacina contendo o mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements